Exporatory clinical study for newly developed drug therapy for preeclampsia with oral nicotinamide

Exporatory clinical study for newly developed drug therapy for preeclampsia with oral nicotinamide - Exporatory clinical study for preeclampsia with oral nicotinamide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029418

Enrollment

Registered

2017-10-04

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

nicotinamide:400mg/day until delivery

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)preeclampsia; diagnosed after preganancy 20wks with BP>=140/90 Protein uria>=300mg/day 2)clinical limitations; chronic hypertension renal dysfunction (creatinine>=1.5mg/dl) vascular disease, SLE, DM hepatitis cerebrovascular disorder 3)clinical examination value; AST, ALT<=105 IU/L Creatinine<=1.5mg/dl Platelet>=100,000 4)written informed consent

Exclusion criteria

Exclusion criteria: 1)pulmonary edema 2)HELLP syndrome 3)non reasuring fetal status 4)estimated fetal body weight<1.5SD oligohydramnios: maximum vertical pocket<2cm intermittent or retrograde umbilical blood flow 5)genital bleeding of unknown origin 6)progression of premature labor 7)allegey for nicotinamide 8)dangerous situations for mother or fetus evaluated by doctors

Design outcomes

Primary

Measure	Time frame
Prolongation of gestational period	—

Countries

Japan

Contacts

Public ContactJunichi Sugawara

Tohoku University graduate School of medicine division of feto-maternal medical science

jsugawara@med.tohoku.ac.jp022-273-6283

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026